Last reviewed · How we verify

Bipolar disorder in remission — Treatment Landscape & Competitive Intelligence

Bipolar disorder in remission (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Bipolar disorder in remission, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Abilify aripiprazole Generic (originally Otsuka/BMS) Third-generation antipsychotic (D2 partial agonist) 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6 2002-11-15
Geodon ziprasidone Pfizer Inc. Atypical antipsychotic (second-generation) Aspartate aminotransferase, cytoplasmic, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A 2001-02-05
Risperdal risperidone Johnson & Johnson (Janssen) Atypical Antipsychotic [EPC] 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6 1993-12-29
Lithium Citrate LITHIUM CITRATE Hikma lithium Glycogen synthase kinase-3 1980-01-01
Lithobid lithium carbonate Generic (multiple manufacturers) Mood stabilizer Inositol-1(or 4)-monophosphatase 1, Glycogen synthase kinase-3 1970-04-06
Tegretol carbamazepine Novartis AG (originally Geigy) Mood Stabilizer [EPC] Frizzled-8, Nuclear receptor subfamily 1 group I member 2, Neuronal acetylcholine receptor; alpha2/beta4 1968-03-11
Mysoline PRIMIDONE Bausch Health Anti-epileptic Agent [EPC] Transient receptor potential cation channel subfamily M member 3 1954-01-01
Phenytoin Sodium PHENYTOIN Viatris Anti-epileptic Agent Sodium channel protein type 2 subunit alpha 1953-01-01
Dilantin Phenytoin Sodium Pfizer phenytoin Nuclear receptor subfamily 1 group I member 3 1953-01-01
Zyprexa Zyprexa Washington University School of Medicine Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 1 drug in Bipolar disorder in remission
  2. AstraZeneca · 1 drug in Bipolar disorder in remission
  3. Bausch Health · 1 drug in Bipolar disorder in remission
  4. Eli Lilly · 1 drug in Bipolar disorder in remission
  5. Enanta Pharmaceuticals, Inc · 1 drug in Bipolar disorder in remission
  6. GSK · 1 drug in Bipolar disorder in remission
  7. Generic (multiple manufacturers) · 1 drug in Bipolar disorder in remission
  8. Generic (originally Otsuka/BMS) · 1 drug in Bipolar disorder in remission
  9. Hikma · 1 drug in Bipolar disorder in remission
  10. Institute of Child Health · 1 drug in Bipolar disorder in remission
  11. Johnson & Johnson (Janssen) · 1 drug in Bipolar disorder in remission
  12. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 1 drug in Bipolar disorder in remission

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Bipolar disorder in remission:

Cite this brief

Drug Landscape (2026). Bipolar disorder in remission — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/bipolar-disorder-in-remission. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing